UNSPSC 51271604: Butanilicaine

This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7X3WV51F4N. European Medicines Agency schedules Butanilicaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06003MIG. Butanilicaine generally arises in the molecular formula C13H19CLN2O.

UNSPSC 51271604 Butanilicaine, a Commodity code, encompasses local anesthetic pharmaceutical products supplied through state and local cooperative purchasing agreements to healthcare facilities and institutions across multiple jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, actively solicits manufacturers of generic pharmaceuticals and over-the-counter products under this code, establishing contracts distributed across participating state and local government facilities. These solicitations typically require vendors to supply products through authorized wholesale distributors with established chargeback systems, comply with current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) requirements, and maintain specific insurance coverage including commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000. State and local procurement offices that purchase through cooperative purchasing vehicles such as MMCAP constitute the primary issuing-body mix, with participation extending across multiple states including Minnesota and Oregon.

MMCAP's RFP S1070000015802 for Generic Multi-Source Pharmaceuticals and Over-the-Counter Products, posted January 20, 2026 with a response deadline of March 26, 2026, exemplifies the active market under this code. Evaluation emphasizes price competitiveness (75 percent), with additional weighted criteria addressing fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Products must be available in the marketplace by May 15, 2026, with resulting contracts effective July 1, 2026 for an initial two-year term and optional extensions through June 30, 2028 for incumbent responders. Vendors must demonstrate pricing flexibility through flat-price, net-price, or WAC-minus pricing structures and maintain contractual relationships with at least two of the three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. All products require FDA compliance, minimum one-year expiration dates from manufacture, and six-month minimum shelf life.